Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584296 · ClinicalTrials.gov registry record · NA
Physical Activity as Self-Management Approach to Improve Health Outcomes in AML
A NA study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT02584296: Completed NA study, sponsored by Virginia Commonwealth University.
NCT02584296 is a NA study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 23 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02584296, a NA study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
Physical Activity as a Self-Management Approach to Improve Health Outcomes in Acute Myeloid Leukemia
Primary Outcome
These aggregated rates will help determine the feasibility of the biobehavioral self-management approach (BSMA) program involving physical activity (PA) in patients receiving consolidation treatment for acute myeloid leukemia (AML). The primary aim of this study rates of recruitment, refusal, retention, and attrition in the BSMA program for patients receiving consolidation treatment for AML will be reported rates of recruitment (number enrolled, refused), retention, and adherence (trends in exer
Interventions
- BEHAVIORAL BSMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-11 |
| Phase | NA |
What the finished NCT02584296 record still lists
NCT02584296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which BSMA is the first listed.
NCT02584296 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02584296 about?
NCT02584296 is a clinical study titled "Physical Activity as Self-Management Approach to Improve Health Outcomes in AML". Physical Activity as a Self-Management Approach to Improve Health Outcomes in Acute Myeloid Leukemia
What is the current status of trial NCT02584296?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2015-03. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02584296?
The interventions under investigation include: BSMA (BEHAVIORAL).
Who is sponsoring clinical trial NCT02584296?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02584296's enrollment target sits among peer trials
23 1755th of 2000 higher than 245 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia